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The Cases
Buruli ulcer (BU) was treated primar-
ily with wide surgical excision until
recent studies confirmed the efficacy of
oral rifampicin combined with intra-
muscular streptomycin. Whether all-
oral antibiotic regimens will be equally
effective is unknown. This report de-
scribes four patients with Mycobacterium
ulcerans infection, all of whom received
rifampicin-based oral antibiotic therapy
followed by surgical resection (three
patients) or oral antibiotics alone (one
patient). Following oral antibiotics for
between 4 and 8 weeks, viable M.
ulcerans was not detectable by culture
in three of the patients, or by histology
in a fourth patient from whom no
specimen for culture was obtained. All
cases spent time in a BU-endemic area
in coastal Victoria, Australia. Baseline
characteristics, diagnosis, treatment re-
ceived, and histopathology of resected
specimens are detailed in Table 1.
Clinical photographs are shown in
Figures 1–4. All patients gave informed
consent for publication.
In all patients, the diagnosis of M.
ulcerans was confirmed by positive poly-
merase chain reaction (PCR) and isola-
tion of M. ulcerans by culture from swabs
obtained prior to treatment. Three pa-
tients had ulcerative lesions (Table 1:
cases 1, 2, and 4; Figures 1, 2, and 4) and
one had a pre-ulcerative lesion (Table 1:
case 3 and Figure 3) from which a saline-
moistened swab of the lesion yielded a
positive PCR and culture. For the two
adults (Table 1: cases 1 and 2), rifampicin
was combined with moxifloxacin for 6
weeks prior to resection. The two chil-
dren (Table 1: cases 3 and 4) received
rifampicin combined with clarithromycin
for either 4 weeks prior to resection
(Table 1: case 3) or 8 weeks without
r e s e c t i o n( T a b l e1 :c a s e4 ) .I nc a s e s1a n d
3, resection specimens were culture-
negative, and culture was not performed
in case 2, although histology showed
resolving inflammation and no acid-fast
bacilli (AFB) by Ziehl-Neelsen staining.
In case 3, a Ziehl-Neelsen stained section
showed persistent AFB but culture was
negative. He had received a reduced dose
of rifampicin due to gastrointestinal and
neurological side effects and underwent
earlier excision than planned at 4 weeks.
Inflammation of surrounding skin and
the size of the lesion reduced during
antibiotic therapy in all four patients
(Figures 1–4). PCR was not performed
on surgical excision specimens (cases 1–
3). Excision and primary closure, rather
than grafting, was achieved in case 2 and
3, which had not been considered
possible initially. Antibiotic treatment
was continued after surgery in all pa-
tients. Total treatment duration was 7
weeks for case 3 and 12 weeks for cases 1
and 2. Case 4 was a 3-year-old girl who
was treated with oral combination anti-
biotics without surgery. After 8 weeks of
rifampicin and clarithromycin syrup, the
ulcer had reduced to a very small
palpable nodule. However, 4 weeks after
ceasing antibiotic therapy the lesion
became inflamed and discharged pus.
Acid-fast bacilli were seen and PCR for
M. ulcerans was positive. However, subse-
quent culture was negative at 3-months,
suggesting an immune-mediated ‘‘para-
doxical reaction’’ driven by residual but
dead mycobacterial cells, rather than a
true failure of oral antibiotic therapy.
Following spontaneous discharge only a
small blind ending sinus remained.
Discussion
BU is a slowly progressive and destruc-
tive soft tissue infection, with the potential
for severe scarring and disability [1,2].
The main burden of disease occurs in sub-
Saharan Africa [1], although in Australia,
there are also active foci in coastal
Victoria, the Daintree region in the far
north, and near Rockhampton, Queens-
land [3–6].
Until recently, the practice of wide
surgical excision followed by grafting has
been the mainstay of treatment [2]. High
relapse rates [7], prohibitive cost, and
limited access to surgery in endemic areas
in Africa led to a renewal of interest in
antibiotic therapy, which had not ap-
peared effective when first studied in field
trials [8–10]. Based on promising ex-
periments in the mouse footpad model
[11–15], a small pilot study established
that the combination of oral rifampicin
and intramuscular (IM) streptomycin for
8 weeks was able to sterilize early BU
lesions in humans. In this small study of
21 pre-ulcerative patients in Ghana, even
4 weeks of rifampicin and streptomycin
led to culture negativity when lesions were
surgically excised after antibiotic treat-
ment of varying durations [16]. Based on
this result, WHO introduced and pro-
moted a new protocol of initial therapy
with 8 weeks of daily oral rifampicin and
IM streptomycin for all patients with BU,
although it was expected that many would
still require surgery [17]. Subsequently,
Chauty et al. reported a case series of
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ulcerative BU who were treated with
this regimen [18]. Of the 215 patients
whose lesions healed, 47% were treated
only with antibiotics and did not require
surgery. Although there were no micro-
biological studies, recurrence of M.
ulcerans infection occurred in only two
patients treated with antibiotics alone. In
a recent randomized trial of 151 patients,
the majority of whom also did not have
surgery, Nienhuis et al. demonstrated
that oral rifampicin plus IM streptomy-
cin for 4 weeks then oral rifampicin plus
oral clarithromycin for 4 weeks was as
effective as 8 weeks of oral rifampicin
plus IM streptomycin [19], indicating
that a shorter duration of IM streptomy-
cin is also effective.
In Australia, surgery is widely accessi-
ble and remains the main treatment
modality for BU, although often in
combination with oral antibiotics. As a
result, the efficacy of surgery alone
compared with oral antibiotics alone is
difficult to establish, although relapses
m a yb el e s sw h e nb o t hm o d a l i t i e sa r e
used [6,20,21]. Australian consensus
guidelines [6], now 4 years old, recom-
mend surgery alone for small lesions or
surgery combined with antibiotic therapy
for more extensive disease. These guide-
lines include the use of IV amikacin for
severe disease, but in practice amikacin is
rarely used due to concerns about
ototoxicity. Other oral antibiotics that
appear to be active against M. ulcerans in
mice include moxifloxacin and clarithro-
mycin [11]. Clarithromycin is preferred
in children due to its established safety
record. There are unpublished accounts
of successful treatment of BU with oral
rifampicin alone (W. Meyers, personal
communication), and the first published
report of successful use of oral antibiotics
was of a North Queensland farmer with
acute, oedematous M. ulcerans disease who
received oral rifampicin, clarithromycin,
and ethambutol for 12 weeks immediately
following extensive but incomplete surgi-
cal excision [20]. The surgical resection
margin showed AFB, but further biopsies
taken after 3 weeks of antibiotics due to
concern about relapse were smear and
culture negative. In retrospect, this ap-
parent clinical deterioration may have
been a ‘‘paradoxical reaction’’ [22] and
the case demonstrated the principle that
oral antibiotics are able to prevent relapse
after incomplete surgical excision, even in
as e v e r ef o r mo fB U .
In the four patients we have described
here, combination oral antibiotic therapy
prior to excision led to the inability to
recover M. ulcerans by culture in the three
cases from whom a second specimen was
submitted for culture, confirming that
oral combinations of antibiotics are capa-
ble of sterilizing lesions in humans, as
Etuafal et al. demonstrated for rifampicin
plus IM streptomcyin. Two of the three
patients we described received oral anti-
biotics for a total of 12 weeks. However,
negative culture results at excision (4
weeks for case 3, 6 weeks for case 1)
Table 1. Baseline Characteristics, Diagnosis, Treatment Received, and Histopathology and Microbiology of Resected Specimens.
Case 1 Case 2 Case 3 Case 4
Age 38-year-old male 32-year-old male 12-year-old male 3-year-old female
Location of lesion Right lateral malleolus Right elbow Lower back Left thigh/buttock
Clinical form, size, and WHO category of
lesion [17]
Ulcer, 2cm diameter,
category 1
Ulcer, 2cm diameter,
srcategory 1
Pre-ulcerative form, 4cm
diameter of induration,
category 1
Ulcer, 2cm diameter, category 1
Region exposed Bellarine Peninsula Bellarine Peninsula Bellarine Peninsula Bellarine Peninsula
Specimen collected for diagnosis Dry swab Dry swab Saline-moistened swab Dry swab
Basis of diagnosis PCR and culture PCR and culture PCR and culture PCR and culture
Date of laboratory diagnosis November 2006 October 2008 November 2008 November 2009
Principal drug Rifampicin
N 600 mg daily
Rifampicin
N 600 mg daily
Rifampicin
N 450 mg daily
N reduced to 600 mg 36
week after day 7
Rifampicin
N 10mg/kg daily
Secondary drug Moxifloxacin
N 400 mg daily
Moxifloxacin
N 400 mg daily
Clarithromycin
N 250 mg twice daily
N reduced to 250 mg twice
daily, alternate days after
day 7
Clarithromycin
N 15mg/kg daily in divided
doses
Duration of oral drug therapy prior to
excision
6 weeks 6 weeks 4 weeks 8 weeks (lesion not excised)
Outcome (follow-up period) No recurrence (36 months) No recurrence (13 months) No recurrence (12 months) Improved to match head sized
palpable nodule
Histology/microbiology summary of
excised specimen (cases 1–3; no excision
case 4)
No AFB, culture negative,
chronic granulomatous
inflammation without
necrosis
No AFB, chronic
necrotizing granulomatous
inflammation, culture not
performed
AFB seen, culture negative,
necrosis to edges of excision
Spontaneous discharge 4
weeks after ceasing antibiotics,
AFB seen, PCR positive, culture
negative
Comment Doses and duration reduced
due to drug intolerance
Apparent relapse due to a
culture negative ‘‘paradoxical’’
reaction [22]
doi:10.1371/journal.pntd.0000770.t001
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effective as suggested for the combination
of rifampicin and streptomycin [16,17].
Dossou et al. also reported clinical
improvement after 8 weeks of oral
rifampicin and clarithromycin [23] in a
pregnant patient. However, in all patients
we have described, the clinical appear-
ance of the lesions only improved slowly
over several weeks. As experience with
antibiotics increases it has become appar-
ent that healing is slow but continues long
Figure 1. Thirty-eight-year-old male with culture confirmed Buruli ulcer before, during, and after treatment.
doi:10.1371/journal.pntd.0000770.g001
www.plosntds.org 3 November 2010 | Volume 4 | Issue 11 | e770Figure 2. Thirty-two-year-old male with culture confirmed Buruli ulcer before, during, and after treatment.
doi:10.1371/journal.pntd.0000770.g002
www.plosntds.org 4 November 2010 | Volume 4 | Issue 11 | e770Figure 3. Twelve-year-old male with culture confirmed Buruli ulcer before, during, and after treatment.
doi:10.1371/journal.pntd.0000770.g003
www.plosntds.org 5 November 2010 | Volume 4 | Issue 11 | e770Figure 4. Three-year-old female with culture confirmed Buruli ulcer before, during, and after treatment.
doi:10.1371/journal.pntd.0000770.g004
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[18,19]. Although this is a small clinical
case series of Category I BU, oral
rifampicin in combination with clarithro-
mycin or moxifloxacin shows promise and
should be further investigated.
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Key Learning Points
N Treatment of patients with limited BU prior to surgery using rifampicin-based
oral antibiotics resulted in culture-negative resection specimens.
N Clinical healing is slow despite the microbiological activity of oral antibiotics.
N Apparent relapses that occur during or after treatment may be due to
immunologically driven paradoxical reactions rather than primary treatment
failure.
N Rifampicin-based oral antibiotic therapy for the treatment of M. ulcerans
infection followed by delayed surgery appears to simplify management by
allowing excision and closure in one step without relapse.
www.plosntds.org 7 November 2010 | Volume 4 | Issue 11 | e770